Showing 2,961 - 2,980 results of 3,304 for search '"clinical trial"', query time: 0.09s Refine Results
  1. 2961

    Safety and tolerability of intramuscular sotrovimab administered at different injection sites: results from the Phase 1 COSMIC study by Jennifer Moore, Alicia Aylott, Wen-Hung Chen, Jerzy Daniluk, Ian A. Hawes, Sergio Parra, Prosenjit Sarkar, Yasmin Sanchez-Pearson, Megan Turner, Amanda Peppercorn, Andrew Skingsley

    Published 2025-12-01
    “…To our knowledge, these are the first data to show that a >2 mL mAb injection into each deltoid muscle is well tolerated.Trial registration ClinicalTrials.gov identifier, NCT05280717…”
    Get full text
    Article
  2. 2962
  3. 2963

    Does the transition from face-to-face to face-to-screen improve oral health literacy? A non-inferiority randomized controlled trial by Negar Ebrahimi, Katayoun Sargeran, Reza Yazdani, Ahmad Reza Shamshiri

    Published 2025-02-01
    “…Trial registration The trial protocol was registered in the Iranian Registry of Clinical Trials (IRCT) on 08–02-2022, (IRCT20220106053643N1|| http://www.irct.ir/ ).…”
    Get full text
    Article
  4. 2964

    Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A... by Ci Song, Peter Kunovszki, Amélie Beaudet

    Published 2022-06-01
    “…**Background:** Agents targeting the prostacyclin (PGI~2~) pathway are important in managing pulmonary arterial hypertension (PAH). No head-to-head clinical trials have compared outcomes between the 3 different PGI~2~-pathway drugs most commonly available in countries with advanced healthcare: oral selexipag, inhaled iloprost, and parenteral (subcutaneous or intravenous) treprostinil. …”
    Get full text
    Article
  5. 2965

    Efficacy and safety of pembrolizumab in patients with advanced endometrial cancer: a systematic review and meta-analysis by Biqiong Pan, Xiaojun Lai, Jiefang Lu, Xiaoyan Bao, Zengke Fan, Jie Sun

    Published 2025-02-01
    “…ObjectiveThis meta-analysis evaluated pembrolizumab monotherapy and combination therapy’s efficacy and safety in recurrent or advanced endometrial cancer (EC).MethodsWe utilized PubMed, Embase, Cochrane Library, and Web of Science databases to identify clinical trials that were used to search literature from July 2013 to July 2023 to evaluate the efficacy and safety of pembrolizumab in patients with advanced EC. …”
    Get full text
    Article
  6. 2966

    Real-World Clinical Outcomes and Treatment Patterns Among Black and Non-Black Patients With Prostate Cancer Initiated on Apalutamide in a Urology Setting by Benjamin H. Lowentritt, Carmine Rossi, Erik Muser, Frederic Kinkead, Bronwyn Moore, Patrick Lefebvre, Dominic Pilon, Shawn Du

    Published 2024-08-01
    “…**Discussion:** While clinical trials have demonstrated the efficacy and safety of apalutamide, there is limited real-world data describing treatment persistence and clinical outcomes among patients with mCSPC and nmCRPC who initiated apalutamide. …”
    Get full text
    Article
  7. 2967
  8. 2968

    Neuromuscular monitoring and incidence of postoperative residual neuromuscular blockade: a prospective observational study by Alessandra Piersanti, Rossella Garra, Fabio Sbaraglia, Miryam Del Vicario, Rosa Lamacchia, Marco Rossi

    Published 2025-01-01
    “…Trial registration The study was registered at ClinicalTrials.gov ( NCT06193213 , date of registration: 05/01/2024).…”
    Get full text
    Article
  9. 2969

    Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review. by Dan-Jie Zhao, Xia Li, Hai-Xia Lin, Hong Zheng, Di Zhou, Peng Tang

    Published 2024-01-01
    “…<h4>Methods</h4>PubMed, Medline, Embase, Web of Science, Clinical Trials Website, and Cochrane Library databases were searched from the time of establishment until January 6, 2024, to compile a list of all randomized controlled trials (RCTs) including upadacitinib in the treatment of moderate-to-severe AD. …”
    Get full text
    Article
  10. 2970
  11. 2971

    Complete metabolic response as early predictor of long-term efficacy after adoptive T cell therapy using tumor-infiltrating lymphocytes by Rikke Andersen, Troels Holz Borch, Eva Ellebaek, Inge Marie Svane, Helle Westergren Hendel, Kasper Madsen

    Published 2025-02-01
    “…In this study the predictive value of early metabolic response after TIL therapy is explored.Materials and methods: 60 patients treated with TIL therapy in 4 different clinical trials and with available [18F]2-fluoro-2-deoxy-d-glucose positron emission tomography-CT (FDG-PET/CT) scans at baseline and at least one follow-up scan 6–8 weeks and/or 12–16 weeks post-TIL infusion were included.Results: Obtaining complete metabolic response (CMR) was associated with significantly superior median overall survival (mOS) compared with not obtaining CMR (p&lt;0.0001). …”
    Get full text
    Article
  12. 2972
  13. 2973

    The Role of Cardiac Resynchronization Therapy in Heart Failure: A Narrative Review by Olivier Uwishema, Ece Karabulut, Dalal Sheikhah, Burhan Kantawala, Misgana Gallo, Fatima Soufan, Magda Wojtara

    Published 2025-01-01
    “…This manuscript conducted a comparative analysis various hallmark clinical trials conducted in lieu of CRT, across many years (2002, 2003, 2004, 2005, 2017, 2018, 2020). …”
    Get full text
    Article
  14. 2974
  15. 2975
  16. 2976
  17. 2977

    Secondary prevention of preeclampsia by Muhammad Ilham Aldika Akbar, Muhammad Ilham Aldika Akbar, Roudhona Rosaudyn, Khanisyah Erza Gumilar, Khanisyah Erza Gumilar, Renuka Shanmugalingam, Gustaaf Dekker, Gustaaf Dekker

    Published 2025-02-01
    “…Proton pump inhibitors (PPIs) have shown potential in lowering soluble FMS-like tyrosine kinase-1 (sFlt-1) levels and enhancing endothelial function, but clinical trials have been inconsistent. Metformin, primarily used for improving insulin sensitivity, has potential advantages in decreasing PE incidence due to its anti-inflammatory and vascular properties, particularly in morbidly obese women. …”
    Get full text
    Article
  18. 2978
  19. 2979
  20. 2980

    Comparison of the safety of remimazolam and propofol during general anesthesia in elderly patients: systematic review and meta-analysis by Xianchun Liu, Longyi Zhang, Li Zhao, Xuelei Zhou, Wei Mao, Linlin Chen, Hongyu Zhu, Ying Xie, Linji Li

    Published 2025-02-01
    “…BackgroundRemimazolam is a novel sedative drug approved for procedural sedation and general anesthesia. Clinical trials have already explored its use in elderly patients for general anesthesia. …”
    Get full text
    Article